Merck’s Winrevair excelled in a phase 3 trial of high-risk pulmonary arterial hypertension patients, reducing the risk of death, lung transplantation and hospitalization by 76% versus placebo. The ...

Merck's stock rose 2% Monday on the back of positive data from a study of a new hypertension drug. MRK stock has declined 7% so far this year, compared to a 5.7% increase for the wider pharmaceutical ...

Merck MRK announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and precapillary ...

Merck's PAH treatment Winrevair is poised for strong uptake in 2025, according to Leerink Partners based on its survey of physicians prescribing the treatment. (Photo by Thomas Frey/picture alliance ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S.

Merck MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending approval of an expanded indication for its ...

Sotatercept-csrk received FDA priority review for PAH treatment based on the ZENITH trial's positive results, showing a 76% reduction in major morbidity and mortality events. The ZENITH trial was a ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...